TY - JOUR
T1 - Reperfusion therapy for ST elevation acute myocardial infarction in Europe
T2 - Description of the current situation in 30 countries
AU - Widimsky, Petr
AU - Wijns, William
AU - Fajadet, Jean
AU - De Belder, Mark
AU - Knot, Jiri
AU - Aaberge, Lars
AU - Andrikopoulos, George
AU - Baz, Jose Antonio
AU - Betriu, Amadeo
AU - Claeys, Marc
AU - Danchin, Nicholas
AU - Djambazov, Slaveyko
AU - Erne, Paul
AU - Hartikainen, Juha
AU - Huber, Kurt
AU - Kala, Petr
AU - Klinčeva, Milka
AU - Kristensen, Steen Dalby
AU - Ludman, Peter
AU - Ferre, Josephina Mauri
AU - Merkely, Bela
AU - Miličić, Davor
AU - Morais, Joao
AU - Noč, Marko
AU - Opolski, Grzegorz
AU - Ostojić, Miodrag
AU - Radovanovič, Dragana
AU - De Servi, Stefano
AU - Stenestrand, Ulf
AU - Studenčan, Martin
AU - Tubaro, Marco
AU - Vasiljević, Zorana
AU - Weidinger, Franz
AU - Witkowski, Adam
AU - Zeymer, Uwe
PY - 2010/4
Y1 - 2010/4
N2 - Aims: Patient access to reperfusion therapy and the use of primary percutaneous coronary intervention (p-PCI) or thrombolysis (TL) varies considerably between European countries. The aim of this study was to obtain a realistic contemporary picture of how patients with ST elevation myocardial infarction (STEMI) are treated in different European countries. Methods and results: The chairpersons of the national working groups/societies of interventional cardiology in European countries and selected experts known to be involved in the national registries joined the writing group upon invitation. Data were collected about the country and any existing national STEMI or PCI registries, about STEMI epidemiology, and treatment in each given country and about PCI and p-PCI centres and procedures in each country. Results from the national and/or regional registries in 30 countries were included in this analysis. The annual incidence of hospital admission for any acute myocardial infarction (AMI) varied between 90-312/100 thousand/year, the incidence of STEMI alone ranging from 44 to 142. Primary PCI was the dominant reperfusion strategy in 16 countries and TL in 8 countries. The use of a p-PCI strategy varied between 5 and 92% (of all STEMI patients) and the use of TL between 0 and 55%. Any reperfusion treatment (p-PCI or TL) was used in 37-93% of STEMI patients. Significantly less reperfusion therapy was used in those countries where TL was the dominant strategy. The number of p-PCI procedures per million per year varied among countries between 20 and 970. The mean population served by a single p-PCI centre varied between 0.3 and 7.4 million inhabitants. In those countries offering p-PCI services to the majority of their STEMI patients, this population varied between 0.3 and 1.1 million per centre. In-hospital mortality of all consecutive STEMI patients varied between 4.2 and 13.5%, for patients treated by TL between 3.5 and 14% and for patients treated by p-PCI between 2.7 and 8%. The time reported from symptom onset to the first medical contact (FMC) varied between 60 and 210 min, FMC-needle time for TL between 30 and 110 min, and FMC-balloon time for p-PCI between 60 and 177 min. Conclusion: Most North, West, and Central European countries used p-PCI for the majority of their STEMI patients. The lack of organized p-PCI networks was associated with fewer patients overall receiving some form of reperfusion therapy.
AB - Aims: Patient access to reperfusion therapy and the use of primary percutaneous coronary intervention (p-PCI) or thrombolysis (TL) varies considerably between European countries. The aim of this study was to obtain a realistic contemporary picture of how patients with ST elevation myocardial infarction (STEMI) are treated in different European countries. Methods and results: The chairpersons of the national working groups/societies of interventional cardiology in European countries and selected experts known to be involved in the national registries joined the writing group upon invitation. Data were collected about the country and any existing national STEMI or PCI registries, about STEMI epidemiology, and treatment in each given country and about PCI and p-PCI centres and procedures in each country. Results from the national and/or regional registries in 30 countries were included in this analysis. The annual incidence of hospital admission for any acute myocardial infarction (AMI) varied between 90-312/100 thousand/year, the incidence of STEMI alone ranging from 44 to 142. Primary PCI was the dominant reperfusion strategy in 16 countries and TL in 8 countries. The use of a p-PCI strategy varied between 5 and 92% (of all STEMI patients) and the use of TL between 0 and 55%. Any reperfusion treatment (p-PCI or TL) was used in 37-93% of STEMI patients. Significantly less reperfusion therapy was used in those countries where TL was the dominant strategy. The number of p-PCI procedures per million per year varied among countries between 20 and 970. The mean population served by a single p-PCI centre varied between 0.3 and 7.4 million inhabitants. In those countries offering p-PCI services to the majority of their STEMI patients, this population varied between 0.3 and 1.1 million per centre. In-hospital mortality of all consecutive STEMI patients varied between 4.2 and 13.5%, for patients treated by TL between 3.5 and 14% and for patients treated by p-PCI between 2.7 and 8%. The time reported from symptom onset to the first medical contact (FMC) varied between 60 and 210 min, FMC-needle time for TL between 30 and 110 min, and FMC-balloon time for p-PCI between 60 and 177 min. Conclusion: Most North, West, and Central European countries used p-PCI for the majority of their STEMI patients. The lack of organized p-PCI networks was associated with fewer patients overall receiving some form of reperfusion therapy.
KW - Acute myocardial infarction
KW - Europe
KW - Incidence
KW - Mortality
KW - Primary angioplasty
KW - Reperfusion therapy
KW - Thrombolysis
UR - http://www.scopus.com/inward/record.url?scp=79955663472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955663472&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehp492
DO - 10.1093/eurheartj/ehp492
M3 - Article
C2 - 19933242
AN - SCOPUS:79955663472
VL - 31
SP - 943
EP - 957
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 8
ER -